Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.70 +0.47 (+1.86%)
Official Closing Price Updated: 7:00 PM EST, Dec 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
From Pfizer Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
Is Pfizer Stock in Trouble?
Via The Motley Fool
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
Got $5,000? These 3 Growth Stocks Are Bargain Buys Right Now.
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments
Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth. 
Via Benzinga
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts. 
Via Benzinga
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Magnificent Dividend Stocks With Yields Above 6% to Buy in December
Via The Motley Fool
Should You Buy More Shares Of Your Loser Stocks?
This is one of the most difficult questions in investing because it’s filled with emotions. Long-term investors tend to stay in losing stocks to try and “make it back” to their breakeven level. 
Via Talk Markets
Topics Stocks / Equities
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Is This a New Reason to Buy Pfizer Stock Hand Over Fist?
Via The Motley Fool
Black Friday Sale for Income Investors: These 3 Ultra-High-Yield Dividend Stocks Are Bargain Buys
Via The Motley Fool
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines. 
Via MarketBeat
Topics Government
Exposures COVID-19 Political Product Safety
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety
Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?
Via The Motley Fool
Advocating for Justice: Supporting Individuals in the Depo-Provera Litigation
Via Get News
Topics Lawsuit
Exposures Financial Legal
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
Via The Motley Fool
Topics Stocks
Exposures US Equities
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel. 
Via Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality. 
Via Benzinga
Exposures Product Safety
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS. 
Via Benzinga
Topics Government
Exposures Political
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.